Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2017

01-12-2017 | Letter to the Editor

Gonorrhea resistance: don’t forget the old chaps

Author: D. Raoult

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2017

Login to get access

Excerpt

I read with great interest the paper by B. Suay-Garcia and M.-T. Pérez-Garcia on Neisseria gonorrhoeae and the resistance to antibiotics [1]. This echoes an over-anxiety generated by the WHO, the CDC and the media about the tragedy of resistance to gonococci, which leaves me unconvinced. Indeed, the tables reveal that there are different levels of resistance to gonococci according to countries, and that no country, for the time being, has observed gonococci that are resistant to everything. Also, a large number of antibiotics has not even been tested in vitro on gonococci as investigators are seeking newly discovered drugs rather than antibiotic compounds already known to be effective against N. gonorrhoeae. A rapid literature search identifies in 30 min at least three such compounds, which are probably effective in 100% of cases. These are pristinamycin [2], fusidic acid [3] and fosfomycin [4]. The real problem of gonorrhea, from my point of view, is to inform doctors in a given country about levels of resistance of gonococci in this area and the choice of an empirical treatment without culture, because it is the most used therapy. This means to test regularly isolates against an extended panel of antibiotics. In practice, in the one-day drama series, gonococcal infections are probably not the most terrifying, especially as treatment failure in gonococcal diseases can be evaluated within a few hours for symptomatic gonorrhea. Moreover, there are efficient drugs available and no need to scream before using these drugs that are cheap and should be as efficient as before [5]. …
Literature
1.
go back to reference Suay-Garcia B, Perez-Gracia MT (2017) Drug-resistant Neisseria gonorrhoeae: latest developments. Eur J Clin Microbiol Infect Dis 36(7):1065–1071CrossRefPubMed Suay-Garcia B, Perez-Gracia MT (2017) Drug-resistant Neisseria gonorrhoeae: latest developments. Eur J Clin Microbiol Infect Dis 36(7):1065–1071CrossRefPubMed
2.
go back to reference Capp AB, Goncalves HD, Silva P, Coutinho AR, Pannunzio FM, Cohen A (1965) Pristinamycin in gonorrhea. Hospital (Rio J) 68(6):1329–1339 Capp AB, Goncalves HD, Silva P, Coutinho AR, Pannunzio FM, Cohen A (1965) Pristinamycin in gonorrhea. Hospital (Rio J) 68(6):1329–1339
3.
go back to reference Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR (2010) Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother 54(10):4518–4519CrossRefPubMedPubMedCentral Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR (2010) Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother 54(10):4518–4519CrossRefPubMedPubMedCentral
4.
go back to reference Hauser C, Hirzberger L, Unemo M, Furrer H, Endimiani A (2015) In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 59(3):1605–1611CrossRefPubMedPubMedCentral Hauser C, Hirzberger L, Unemo M, Furrer H, Endimiani A (2015) In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 59(3):1605–1611CrossRefPubMedPubMedCentral
5.
go back to reference Dubourg G, Abat C, Raoult D (2017) Why new antibiotics are not obviously useful now. Int J Antimicrob Agents 49(5):549–553 Dubourg G, Abat C, Raoult D (2017) Why new antibiotics are not obviously useful now. Int J Antimicrob Agents 49(5):549–553
Metadata
Title
Gonorrhea resistance: don’t forget the old chaps
Author
D. Raoult
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-3099-0

Other articles of this Issue 12/2017

European Journal of Clinical Microbiology & Infectious Diseases 12/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.